Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

International Journal of Cardiology

Volumn 71, Issue 3, 1999, Pages 273-281

  Cohen, Marc ^a   Théroux, Pierre ^b   Weber, Simon ^c   Laramée, Pierre ^d   Huynh, Thao ^e   Borzak, Steven ^f   Diodati, Jean G ^g   Squire, Iain B ^h   Deckelbaum, Lawrence I ⁱ   Thornton, Annemarie R ⁱ   Harris, Katherine E ⁱ   Sax, Frederic L ⁱ   Lo, Man Wai ⁱ   White, Harvey D ^j  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c Hospital Cochin ^*  (France)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f HENRY FORD HOSPITAL   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j GREEN LANE HOSPITAL   (New Zealand)

more..

Author keywords

Bleeding time; Enoxaparin; Low molecular weight heparin; Platelet aggregation; Tirofiban; Unstable angina

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ARTICLE; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION INHIBITION;

ANGINA, UNSTABLE; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SAFETY; SYNDROME; TREATMENT OUTCOME; TYROSINE;

EID: 0344641920     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(99)00171-0     Document Type: Article

References (17)

1. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452.
2. Antman E.M., McCabe C.H., Premmereur J., Gurfinkel F.F., Bemink J.L.M., Turpie G.G., et al. Enoxaparin for the acute and chronic management of unstable angina/non-Q-wave myocardial infarction: results of TIMI 11B. Circulation. 98:(Suppl 1(17)):1998;1-504.
3. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 338:(21):1998;1498-1505.
5. Inhibition of the glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:(21):1998;1488-1497.
6. Effects of glycoprotein IIb/IIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
7. Inhibition of glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
8. Deckelbaum L.I., Sax F.L., Grossman W. Tirofiban, a nonpeptide inhibitor of the glycoprotein IIb/IIIa receptor. New therapeutic agents in thrombosis and thrombolysis. 1997;Marcel Dekker Inc.
9. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 337:(10):1997;688-698.
10. Waters D., Azar R.R. Low-molecular-weight heparins for unstable angina. A better mousetrap? Circulation. 96:1997;3-5.
11. Antman E.M., Cohen M., Radley D., McCabe C.H., Premmereur J., Braunwald E. Enoxaparin for unstable angina/non-Q-wave myocardial infarction: meta-analysis of TIMI 11B and ESSENCE. J Am Coll Cardiol. 33:(Suppl A):1999;351A.
12. Hand E.L., Gilbert J.R., Yuan A.S., Olah T.V., Hichens M. Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay. J Pharm Biomed Anal. 12:(8):1994;1047-1053.
13. Bovill E.G., Term M.L., Stump D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), Phase II Trial. Ann Intern Med. 115:1991;256-265.
14. Salzman E.W., Rosenberg R.D., Smith M.H., Lindon J.N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 65:1980;64-73.
15. Xiao Z., Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256.
16. ®, low molecular weight heparin) and aspirin: potential interactive effects on pharmacodynamics and pharmacokinetics in anesthetized mongrel dogs. 1997;Merck Research Laboratories. June 30.
17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.